Last reviewed 2026-04-20 · How we verify

Dialferine (ALCURONIUM)

FDA-approved active Small molecule Quality 15/100

Dialferine (generic name: ALCURONIUM) is a alcuronium drug. It is currently FDA-approved.

Alcuronium (Dialferine) is a marketed neuromuscular blocking agent that competes in the same class as tubocurarine and dimethyltubocurarinium. Its key strength lies in its mechanism of action, effectively blocking acetylcholine at the neuromuscular junction, which is critical for surgical procedures requiring muscle relaxation. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic name	ALCURONIUM
Drug class	alcuronium
Target	Neuronal acetylcholine receptor subunit alpha-2, Neuronal acetylcholine receptor subunit alpha-7, Muscarinic acetylcholine receptor M1
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Dialferine CI brief — competitive landscape report
Dialferine updates RSS · CI watch RSS

Frequently asked questions about Dialferine

What is Dialferine?

Dialferine (ALCURONIUM) is a alcuronium drug.

What is the generic name of Dialferine?

ALCURONIUM is the generic (nonproprietary) name of Dialferine.

What drug class is Dialferine in?

Dialferine belongs to the alcuronium class. See all alcuronium drugs at /class/alcuronium.

What development phase is Dialferine in?

Dialferine is FDA-approved (marketed).

What does Dialferine target?

Dialferine targets Neuronal acetylcholine receptor subunit alpha-2, Neuronal acetylcholine receptor subunit alpha-7, Muscarinic acetylcholine receptor M1 and is a alcuronium.

Drug class: All alcuronium drugs
Target: All drugs targeting Neuronal acetylcholine receptor subunit alpha-2, Neuronal acetylcholine receptor subunit alpha-7, Muscarinic acetylcholine receptor M1
Therapeutic area: All drugs in Neuroscience

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing